Cytek Biosciences Inc. (CTKB)
Cytek Biosciences Statistics
Share Statistics
Cytek Biosciences has 128.1M shares outstanding. The number of shares has increased by -2.42% in one year.
| Shares Outstanding | 128.1M |
| Shares Change (YoY) | -2.42% |
| Shares Change (QoQ) | -0.55% |
| Owned by Institutions (%) | 58.97% |
| Shares Floating | 116.09M |
| Failed to Deliver (FTD) Shares | 70 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.47M, so 2.7% of the outstanding shares have been sold short.
| Short Interest | 3.47M |
| Short % of Shares Out | 2.7% |
| Short % of Float | 2.97% |
| Short Ratio (days to cover) | 4.85 |
Valuation Ratios
The PE ratio is -140.81 and the forward PE ratio is 39.13. Cytek Biosciences's PEG ratio is 2.89.
| PE Ratio | -140.81 |
| Forward PE | 39.13 |
| PS Ratio | 4.23 |
| Forward PS | 1.4 |
| PB Ratio | 2.14 |
| P/FCF Ratio | 38.79 |
| PEG Ratio | 2.89 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Cytek Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.86, with a Debt / Equity ratio of 0.02.
| Current Ratio | 5.86 |
| Quick Ratio | 5.21 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.37 |
| Debt / FCF | 0.35 |
| Interest Coverage | -3.92 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $309.34K |
| Profits Per Employee | $-9.29K |
| Employee Count | 648 |
| Asset Turnover | 0.4 |
| Inventory Turnover | 2.04 |
Taxes
| Income Tax | 320K |
| Effective Tax Rate | -5.61% |
Stock Price Statistics
The stock price has increased by -44.13% in the last 52 weeks. The beta is 1.41, so Cytek Biosciences's price volatility has been higher than the market average.
| Beta | 1.41 |
| 52-Week Price Change | -44.13% |
| 50-Day Moving Average | 4.57 |
| 200-Day Moving Average | 5.53 |
| Relative Strength Index (RSI) | 33.38 |
| Average Volume (20 Days) | 895.99K |
Income Statement
In the last 12 months, Cytek Biosciences had revenue of 200.45M and earned -6.02M in profits. Earnings per share was -0.05.
| Revenue | 200.45M |
| Gross Profit | 111.11M |
| Operating Income | -20.52M |
| Net Income | -6.02M |
| EBITDA | -20.52M |
| EBIT | -20.52M |
| Earnings Per Share (EPS) | -0.05 |
Balance Sheet
The company has 98.72M in cash and 7.55M in debt, giving a net cash position of 91.16M.
| Cash & Cash Equivalents | 98.72M |
| Total Debt | 7.55M |
| Net Cash | 91.16M |
| Retained Earnings | -35.2M |
| Total Assets | 499.5M |
| Working Capital | 328.78M |
Cash Flow
In the last 12 months, operating cash flow was 25.38M and capital expenditures -3.52M, giving a free cash flow of 21.85M.
| Operating Cash Flow | 25.38M |
| Capital Expenditures | -3.52M |
| Free Cash Flow | 21.85M |
| FCF Per Share | 0.17 |
Margins
Gross margin is 55.43%, with operating and profit margins of -10.24% and -3%.
| Gross Margin | 55.43% |
| Operating Margin | -10.24% |
| Pretax Margin | -2.84% |
| Profit Margin | -3% |
| EBITDA Margin | -10.24% |
| EBIT Margin | -10.24% |
| FCF Margin | 10.9% |
Dividends & Yields
CTKB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CTKB is $7, which is 98.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 98.9% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 3.63 |
| Piotroski F-Score | 4 |